대한방사성의약품학회지 (Journal of Radiopharmaceuticals and Molecular Probes)

  • 제6권2호
  • /
  • Pages.116-130
  • /
  • 2020
  • /
  • 2384-1583(pISSN)
  • /
  • 2508-3848(eISSN)
대한방사성의약품학회 (Korean Society of Radiopharmaceuticals and Molecular Probes)
권호 표지
DOI QR코드

DOI QR Code

Current research status for imaging neuroinflammation by PET

  • Namhun Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences) ;
  • Jae Yong Choi (Division of Applied RI, Korea Institute of Radiological & Medical Sciences)
  • 투고 : 2020.12.14
  • 심사 : 2020.12.29
  • 발행 : 2020.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The aging society is globally one of biggest issue because it is related with various degenerative brain disease such as dementia, Parkinson's disease, Alzheimer's disease, multiple sclerosis, and cerebrovascular disease. These diseases are characterized by misfolded-protein aggregation; another pathological trait is "neuroinflammation". In physiological state, the resting microglia cells are activated and it removes abnormal synapses and cell membrane debris to maintain the homeostasis. In pathological state, however, microglia undergo morphological change form 'resting' to 'activated amoeboid phenotype' and the microglia cells are accumulated by neuronal damage, the inflammatory reactions induced nerve metamorphosis with a variety of neurotoxic factors including cytokines, chemokines, and reactive oxygen species. Thus, the activated microglia cell with various receptors (TSPO, COX, CR, P2XR, etc.) was perceived as important biomarkers for imaging the inflammatory progression. In this review, we would like to introduce the current status of the development of radiotracers that can image activated microglia.

키워드

과제정보

This study was supported by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), by the Ministry of Science and ICT (MSIT), Republic of Korea (No. 50536-2020).

참고문헌

  1. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science 2016;353:777-783.
  2. Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 2016;13:3391-3396.
  3. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: A pathological perspective. J Neuroinflammation 2004;1:1-4.
  4. Janssen B, Mach RH. Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease. Prog Mol Biol Transl Sci 2019;165:371-399.
  5. Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: Outlook beyond TSPO. Mol Imaging 2018;17:1-25.
  6. Tronel C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Dupont AC, Arlicot N. Molecular targets for PET imaging of activated nicroglia: The current situation and future expectations. Int J Mol Sci 2017;18:1-22.
  7. Larry J, James MO, Brian JC, Robert AK, G. Leonard W, Douglas MJ, Paul EM, Donald MW., Michael RK, Simon SR, William RM, David EK, Harry SG, Anne BY. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Annals of Neurology 1989;26:752-758.
  8. Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and old TSPO PET radioligands for imaging brain microglial activation in neurodegenerative disease. Curr Neurol Neurosci Rep 2019;19:1-10.
  9. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, Nozaki S, Fujimura Y, Koeda M, Asada T, Suhara T. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008;64:835-841.
  10. Varrone A, Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyas B, Borg J, Boellaard R, AlTawil N, Eriksdotter M, Zimmermann T, SchultzeMosgau M, Thiele A, Hoffmann A, Lammertsma AA, Halldin C. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging 2013;40:21-31.
  11. Zanotti-Fregonara P, Pascual B, Veronese M, Yu M, Beers D, Appel SH, Masdeu JC. Head-to-Head comparison of 11C-PBR28 and 11C-ER176 for quantification of the translocator protein in the human brain. Eur J Nucl Med Mol Imaging 2019;46:1822-1829.
  12. Fujimura Y, Zoghbi SS, Simeon FG, Taku A, Pike VW, Innis RB, Fujita M. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, 18F-PBR06. J Nucl Med 2009;50:1047-1053.
  13. Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, Mizrahi R. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011;31:1807-1816.
  14. Miyoshi M, Ito H, Arakawa R, Takahashi H, Takano H, Higuchi M, Okumura M, Otsuka T, Kodaka F, Sekine M, Sasaki T, Fujie S, Seki C, Maeda J, Nakao R, Zhang MR, Fukumura T, Matsumoto M, Suhara T. Quantitative analysis of peripheral benzodiazepine receptor in the human brain using PET with 11C-AC-5216. J Nucl Med 2009;50:1095-1101.
  15. Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC, Reynolds A, Hilton J, Dannals RF, Kassiou M. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009;50:1276-1282.
  16. Guo Q, Colasanti A, Owen DR, Onega M, Kamalakaran A, Bennacef I, Matthews PM, Rabiner EA, Turkheimer FE, Gunn RN. Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: A genetic polymorphism effect on in vivo binding. J Nucl Med 2013;54:1915-1923.
  17. Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H, Dauphinot L, Bertoux M, Dubois B, Gervais P, Colliot O, Potier MC, Bottlaender M, Sarazin M. ㄹEarly and protective microglial activation in Alzheimer's disease: A prospective study using 18F-DPA-714 PET imaging. Brain 2016;139:1252-1264.
  18. Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, Wang J, Xu H, Wang L, Liang SH. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharmaceutica Sinica B 2020;In press.
  19. Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, Searle G, Goldstone AP, Brooks DJ, Nicholas RS, Trigg W, Gunn RN, Sharp DJ. Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. Eur J Nucl Med Mol Imaging 2016;43:2201-2210.
  20. Sakata M, Ishibashi K, Imai M, Wagatsuma K, Ishii K, Hatano K, Ishiwata K, Toyohara J. Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteers. EJNMMI Res 2017;7:1-9.
  21. Moon BS, Jung JH, Park HS, Contino M, Denora N, Lee BC, Kim SE. Preclinical comparison study between [18F]Fluoromethyl-PBR28 and its deuterated analog in a rat model of neuroinflammation. Bioorg Med Chem Lett 2018;28:2925-2929.
  22. Yui J, Maeda J, Kumata K, Kawamura K, Yanamoto K, Hatori A, Yamasaki T, Nengaki N, Higuchi M, Zhang MR. 18F-FEAC and 18F-FEDAC: Pet of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain. J Nucl Med 2010;51:1301-1309.
  23. Ohnishi A, Senda M, Yamane T, Sasaki M, Mikami T, Nishio T, Ikari Y, Nishida H, Shukuri M, Takashima T, Mawatari A, Doi H, Watanabe Y, Onoe H. Human whole-body diodistribution and dosimetry of a New PET tracer, [11C]ketoprofen methyl ester, for imagings of neuroinflammation. Nucl Med Biol 2014;:594-599.
  24. Shrestha S, Singh P, Cortes-Salva MY, Jenko KJ, Ikawa M, Kim MJ, Kobayashi M, Morse CL, Gladding RL, Liow JS, Zoghbi SS, Fujita M, Innis RB, Pike VW. 3-Substituted 1,5-diaryl-1H-1,2,4-triazoles as prospective PET radioligands for imaging brain COX-1 in monkey. Part 2: Selection and evaluation of [11C]PS13 for quantitative imaging. ACS Chem Neurosci 2018;9:2620-2627.
  25. Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, Singh P, Cortes MY, Henry K, Tye GL, Frankland MP, Montero Santamaria JA, Liow JS, Zoghbi SS, Fujita M, Pike VW, Innis RB. First-in-human evaluation of [11C]PS13, a Novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging 2020.
  26. de Vries EF, Doorduin J, Dierckx RA, van Waarde, A. Evaluation of [11C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol 2008;35:35-42.
  27. Kumar JSD, Bai B, Zanderigo F, DeLorenzo C, Prabhakaran J, Parsey RV, Mann JJ. In vivo brain imaging, biodistribution, and radiation dosimetry estimation of [11C]celecoxib, a COX-2 PET ligand, in nonhuman primates. Molecules 2018;23:1-11.
  28. Prabhakaran J, Underwood MD, Parsey RV, Arango V, Majo VJ, Simpson NR, Van Heertum R, Mann JJ, Kumar JS. Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide as a PET imaging probe for COX-2 expression. Bioorg Med Chem 2007;15:1802-1807.
  29. Kumar JSD, Zanderigo F, Prabhakaran J, RubinFalcone H, Parsey RV, Mann JJ. In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons. Bioorg Med Chem Lett 2018;28:3592-3595.
  30. Prabhakaran J, Underwood M, Zanderigo F, Simpson NR, Cooper AR, Matthew J, Rubin-Falcone H, Parsey RV, Mann JJ, Dileep Kumar JS. Radiosynthesis and in vivo evaluation of [11C]MOV as a PET imaging agent for COX-2. Bioorg Med Chem Lett 2018;28:2432-2435.
  31. Kim MJ, Shrestha SS, Cortes M, Singh P, Morse C, Liow JS, Gladding RL, Brouwer C, Henry K, Gallagher E, Tye GL, Zoghbi SS, Fujita M, Pike VW, Innis RB. Evaluation of two potent and selective PET radioligands to Image COX-1 and COX-2 in rhesus monkeys. J Nucl Med 2018;59:1907-1912.
  32. Shrestha S, Kim MJ, Eldridge M, Lehmann ML, Frankland M, Liow JS, Yu ZX, Cortes-Salva M, Telu S, Henter ID, Gallagher E, Lee JH, Fredericks JM, Poffenberger C, Tye G, Ruiz-Perdomo Y, Anaya FJ, Montero Santamaria JA, Gladding RL, Zoghbi SS, Fujita M, Katz JD, Pike VW, Innis RB. PET measurement of cyclooxygenase-2 using a novel radioligand: Upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation 2020;17:1-17.
  33. Evens N, Vandeputte C, Coolen C, Janssen P, Sciot R, Baekelandt V, Verbruggen AM, Debyser Z, Van Laere K, Bormans GM. Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer. Nucl Med Biol 2012;39:389-399.
  34. Moldovan RP, Teodoro R, Gao Y, Deuther-Conrad W, Kranz M, Wang Y, Kuwabara H, Nakano, M, Valentine H, Fischer S, Pomper MG, Wong DF, Dannals RF, Brust P, Horti AG. Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor. J Med Chem 2016;59:7840-7855.
  35. Evens N, Bosier B, Lavey B J, Kozlowski JA, Vermaelen P, Baudemprez L, Busson R, Lambert DM, Van Laere K, Verbruggen AM, Bormans GM. Labelling and biological evaluation of [11C]methoxy-Sch225336: A radioligand for the cannabinoid-type 2 receptor. Nucl Med Biol 2008;35:793-800.
  36. Attili B, Celen S, Ahamed M, Koole M, Haute CVD, Vanduffel W, Bormans G. Preclinical evaluation of [18F]MA3: A CB2 receptor agonist radiotracer for PET. Br J Pharmacol 2019;176:1481-1491.
  37. Riko F, Kiichi I, Motohiro K, Shin-ichi I, Noriko S, Jun-ichi S, Kazutoyo E, Fumio S, Michio S. Carbon11-labeled KF15372: A potential central nervous system adenosine A1 receptor ligand. J. Nucl. Med 1995;37:1203-1207.
  38. Matsuya T, Takamatsu H, Murakami Y, Noda A, Ichise R, Awaga Y, Nishimura S. Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain. Nucl Med Biol 2005;32:837-844.
  39. Junko NK, Riko F, Jun-ichi SMK, Shin-ichi I, Kazutoyo E, Fumio S, Michio S. Evaluation of Carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. Nucl. Med. Biol. 1997;24:53-59.
  40. Mishina M, Ishii K, Kimura Y, Suzuki M, Kitamura S, Ishibashi K, Sakata M, Oda K, Kobayashi S, Kimura K, Ishiwata K. Adenosine A1 receptors measured with 11C-MPDX PET in early Parkinson's disease. Synapse 2017;71.
  41. Mishina M, Kimura Y, Sakata M, Ishii K, Oda K, Toyohara J, Kimura K, Ishiwata K. Age-related decrease in male extra-striatal Adenosine A1 receptors measured using 11C-MPDX PET. Front Pharmacol 2017;8:1-7.
  42. Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, Coenen HH, Zilles K. In vivo imaging of Adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage 2003;19:1760-1769.
  43. Elmenhorst D, Kroll T, Wedekind F, Weisshaupt A, Beer S, Bauer A. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 Adenosine receptors: Validation by displacement and autoradiographic experiments. J Nucl Med 2013;54:1411-1419.
  44. Wei-Fang W, Kiichi I, Hiromi N, Shin-ichi I, Motohiro K, Jun-ichi S, Fumio S, Michio S. Carbon-11-labeled KF21213: A highly selective ligand for mapping CNS Adenosine A2A receptors with positron emission tomography. Nucl. Med. Biol. 2000;27:541-546.
  45. Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K. Adenosine A2A receptors measured with [11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011;6:e17338.
  46. Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of Adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 2005;32:405-413.
  47. Sakata M, Ishibashi K, Imai M, Wagatsuma K, Ishii K, Zhou X, de Vries EFJ, Elsinga PH, Ishiwata K, Toyohara J. Initial evaluation of an Adenosine A2A receptor ligand, 11C-Preladenant, in healthy human subjects. J Nucl Med 2017;58:1464-1470.
  48. Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, Kase H, Kilborn J, Martindill S, Mori A. Positron emission tomography analysis of [11C] KW-6002 binding to human and rat Adenosine A2A receptors in the brain. Synapse 2008;62: 671-681.
  49. Janssen B, Vugts DJ, Funke U, Spaans A, Schuit RC, Kooijman E, Rongen M, Perk LR, Lammertsma AA, Windhorst AD. Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [11C] A-740003 as a novel tracer of neuroinflammation. J Labelled Comp Radiopharm 2014;57:509-516.
  50. Ory, D., Celen, S., Gijsbers, R., Van Den Haute, C., Postnov, A., Koole, M., Vandeputte, C., Andres, J. I., Alcazar, J., De Angelis, M., Langlois, X., Bhattacharya, A., Schmidt, M., Letavic, M. A., Vanduffel, W., Van Laere, K., Verbruggen, A., Debyser, Z., Bormans, G. Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med 2016;57:1436-1441.
  51. Van Weehaeghe, D., Koole, M., Schmidt, M. E., Deman, S., Jacobs, A. H., Souche, E., Serdons, K., Sunaert, S., Bormans, G., Vandenberghe, W., Van Laere, K. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: Human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. Eur J Nucl Med Mol Imaging 2019;46:2051-2064.
  52. Hagens, M. H. J., Golla, S. S. V., Janssen, B., Vugts, D. J., Beaino, W., Windhorst, A. D., O'Brien-Brown, J., Kassiou, M., Schuit, R. C., Schwarte, L. A., de Vries, H. E., Killestein, J., Barkhof, F., van Berckel, B. N. M., Lammertsma, A. A. The P2X7 receptor tracer [11C] SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: A first-in man study. Eur J Nucl Med Mol Imaging 2020;47:379-389.
  53. Koole, M., Schmidt, M. E., Hijzen, A., Ravenstijn, P., Vandermeulen, C., Van Weehaeghe, D., Serdons, K., Celen, S., Bormans, G., Ceusters, M., Zhang, W., Van Nueten, L., Kolb, H., de Hoon, J., Van Laere, K. 18F-JNJ-64413739, a novel PET ligand for the P2X7 ion channel: Radiation dosimetry, kinetic modeling, test-retest variability, and occupancy of the P2X7 antagonist JNH-54175446. J Nucl Med 2019;60:683-690.
  54. Okamura T, Okada M, Kikuchi T, Wakizaka H, Zhang MR. A 11C-labeled 1,4-dihydroquinoline derivative as a potential PET tracer for imaging of redox status in mouse brain. J Cereb Blood Flow Metab 2015;35:1930-1936.
  55. Zhang W, Cai Z, Li L, Ropchan J, Lim K, Boutagy NE, Wu J, Stendahl JC, Chu W, Gropler R, Sinusas AJ, Liu C, Huang Y. Optimized and automated radiosynthesis of [18F]DHMT for translational imaging of reactive oxygen species with positron emission tomography. Molecules 2016;21:1-11.
  56. Hou C, Hsieh CJ, Li S, Lee H, Graham TJ, Xu K, Weng CC, Doot RK, Chu W, Chakraborty SK, Dugan LL, Mintun MA, Mach RH. Development of a positron emission tomography radiotracer for imaging elevated levels of superoxide in neuroinflammation. ACS Chem Neurosci 2018;9:578-586.
  57. Philipp MM, Karl S, Kai K, Georg B, Swen H, Dominique W, Anke H, Marianne P, Dietlind S, Florian W, Donald L, Henryk B, Peter B, Hermann JG, Osama S, Johannes S. Reduced α4β2*-Nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry 2009;66:866-877.
  58. Ding YS, Fowler JS, Logan J, Wang GJ, Telang F, Garza V, Biegon A, Pareto D, Rooney W, Shea C, Alexoff D, Volkow ND, Vocci F. 6-[18F] fluoro-A85380, a new PET tracer for the nicotinic acetylcholine receptor: Studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 2004;53: 184-189.
  59. Mukherjee J, Lao PJ, Betthauser TJ, Samra GK, Pan ML, Patel IH, Liang C, Metherate R, Christian BT. Human brain imaging of nicotinic acetylcholine α4β2 receptors using [18F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. J Comp Neurol 2018;526:80-95.
  60. Toyohara J, Sakata M, Wu J, Ishikawa M, Oda K, Ishii K, Iyo M, Hashimoto K, Ishiwata K. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009;23:301-309.
  61. Hillmer AT, Zheng MQ, Li S, Scheunemann M, Lin SF, Holden D, Labaree D, Ropchan J, Teodoro R, Deuther-Conrad W, Carson RE, Brust P, Huang Y. PET imaging evaluation of [18F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates. Eur J Nucl Med Mol Imaging 2016;43: 537-547.
  62. Hillmer AT, Li S, Zheng MQ, Scheunemann M, Lin SF, Nabulsi N, Holden D, Pracitto R, Labaree D, Ropchan J, Teodoro R, Deuther-Conrad W, Esterlis I, Cosgrove KP, Brust P, Carson RE, Huang Y. PET imaging of α7 nicotinic acetylcholine receptors: A comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F] ASEM in humans. Eur J Nucl Med Mol Imaging 2017;44:1042-1050.
  63. Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, Wang Y, Mathews WB, Wu Y, Hall A, LaCourse C, Ahn HH, Nam H, Lesniak WG, Valentine H, Pletnikova O, Troncoso JC, Smith MD, Calabresi PA, Savonenko AV, Dannals RF, Pletnikov MV, Pomper MG. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci USA 2019;116:1686-1691.
  64. Tanzey SS, Shao X, Stauff J, Arteaga J, Sherman P, Scott PJH, Mossine AV. Synthesis and initial in vivo evaluation of [11C]AZ683 - A novel PET radiotracer for colony stimulating factor 1 receptor (CSF1R). Pharmaceuticals (Basel) 2018;11:1-14.